Sphingosine-1-phosphate (S1P) a bioactive lipid is produced in its primary 31 reservoir, erythrocytes by an enzyme Sphingosine kinase-1 (SphK-1). The 32 activation of such kinases and the subsequent S1P generation and secretion in 33 the blood serum represent a major regulator of many cellular signaling 34 cascades. Orthologue of sphingosine kinases 1 and 2 (SphK-1 and 2) that 35 catalyze the phosphorylation of sphingosine generating S1P are not present in 36 malaria parasite. The malaria parasite, Plasmodium falciparum, is an 37 intracellular obligatory organism that reside in the human erythrocyte during its 38 blood stage life cycle and orchestrates many metabolic interactions with host for 39 its survival. Given the regulatory role of S1P, we targeted host SphK-1 by a 40 generic pharmacological inhibitor N,N-Dimethyl-sphingosine (DMS) and 41 analyzed growth of intra-erythrocytic parasite. We found that reducing S1P 42 levels by inhibiting host SphK-1 activity led to halted parasite growth and 43 ultimately cell death. Reduced intracellular S1P levels were attributed to 44 decreased glycolysis marked by the low uptake of glucose by parasite and by 45 less production of lactate, a byproduct of glycolysis. Reduced glycolysis was 46 mediated by decrease translocation of the glycolytic enzyme, Glyceraldehyde 3-47 52 53 3 Author Summary 54 Erythrocytes membrane enzyme Sphingosine kinase-1 (SphK-1) produces 55 Sphingosine-1-phosphate (S1P) a bioactive lipid by phosphorylation of 56 Sphingosine (Sph). S1P generated by activation of SphK is prosurvival signal 57 and regulate cell growth. The malaria parasite, Plasmodium falciparum, is an 58 intracellular obligatory pathogen that reside in erythrocyte during its blood stage 59 life cycle and orchestrates many metabolic interactions with its host 60 erythrocytes for survival. Orthologue of SphK-1/ 2 are not present in malaria 61 parasite, therefore treatment with SphK inhibitor targeted host SphK-1 and led 62 to reduced S1P level. The reduction in host S1P led to halted parasite growth 63 and cell death. Furthermore, reduced erythrocyte S1P levels led to decreased 64 glycolysis marked by the low uptake of glucose by parasite and by less 65 production of lactate. Erythrocyte SphK-1 being a host encoded enzyme, is 66 resistance safe and represents a potent target for the development of 67 therapeutics against intra-erythrocytic P. falciparum. 68 69 70 71 72 73 74 75 76 77 78 130 phosphorylated product of sphingosine produced by kinases, sphingosine 131 kinase-1 and -2 (SphK-1 and SphK-2)[28]. While SphK-1 is localized to the 132 157 Materials and methods 158 Cultivation of P. falciparum-infected erythrocytes 159 7
phosphate dehydrogenase (GAPDH) to the cytosol of infected erythrocytes and 48 cell death. Knocking down of erythrocyte SphK-1 is not lethal to the host and 49 being a host encoded enzyme, targeting it with safe and specific drugs will not 50 lead to the problem of resistance; thus, SphK-1 represents a potent target for the 51 development of therapeutics against intra-erythrocytic P. falciparum.
Introduction 79 An estimate of 219 million malaria cases and 435,000 related deaths were 80 reported in 2017 worldwide according to World Health Organization [1] . The 81 decrease in efficiency of current anti-malarial agents including artemisinin, 82 quinine, chloroquine, piperaquine, mefloquine and their derivatives in malaria 83 affected regions of the world has significantly increased the cost and complexity 84 of curing malaria[2] , [3] , [4] . The limited number of available anti-malarial drugs 85 and parasitic resistance to almost every available chemical therapy continues to 86 spur the search for novel approaches. The next generation of anti-malarials are 87 in pipeline and holds a great promise as they target novel parasite encoded 88 enzymes and molecular pathways[5] , [6] . However, since these drugs target 89 molecules that are under genetic control of the parasite, resistance against them 90 can be developed in the long run[7] , [8] . To deal with the nuisance of drug 91 resistance, targeting host encoded proteins that are indispensable for parasite 92 growth and survival would be an ideal situation. Since, the chances of 93 development of resistance against non-parasite targets are very bleak, host 94 targeted drug development will be a classical addition to the field of drug 95 discovery in malaria. 96 P. falciparum being an intracellular obligatory parasite exploits the host's 97 resources and pathways for its survival and growth. For example, parasite feeds 98 on erythrocytic hemoglobin content during the asexual blood stage 99 development. The breakdown of hemoglobin provides amino acids for its 100 growth and maturation [9] . Another important example is the metabolic pathway 101 of glycolysis. It is well known that the parasite infected erythrocytes utilize 102 glucose at a much higher rate than the normal parasite uninfected 103 erythrocytes[10] , [11] . During the intra-erythrocytic growth phase, Plasmodium 104 lacks a functional tricarboxylic acid (TCA) cycle (also known as Krebs cycle) 105 5 and is therefore, dependent on glycolysis for its energy requirements [12] . For 106 glycolysis, the parasite makes use of pre-existing pools of host glucose as well 107 as imports it by expressing glucose transporters on the surface of the host 108 erythrocytes [13] . The parasite's sole dependence on glycolysis for energy needs 109 makes it a potential target for anti-malarial chemotherapies. However, the 110 regulation of glycolysis by parasites in infected erythrocytes is not very 111 clear [14] , [15] , [16] . 112 A recent study demonstrates that intracellular S1P facilitates glycolysis in 113 erythrocytes in response to hypoxia [17] . This biolipid is involved in various 114 other biological processes including immune response [18] [24] . Several reasons have been held responsible for the elevated 121 S1P content in these cells including high sphingosine kinase (SphK) activity, 122 lack of S1P degrading enzymes (S1P lyase and S1P phosphohydrolase) and its 123 capability to import sphingosine from extracellular environment[25] , [26] . 124 Surprisingly, the role of multi-faceted S1P in erythrocytes and what affect it 125 exerts on the physiology of the cells remains an unexplored mystery. S1P is 126 produced through hydrolysis of sphingomyelin to ceramide by 127 sphingomyelinases, followed by sphingosine synthesis from ceramide via the 128 action of cermidases, and finally phosphorylation of sphingosine via 129 sphingosine kinases (SphK) produces S1P [27] . S1P is basically a 6 cytosol, SphK-2 resides in the nucleus[29] , [30] . Erythrocytes harbor only SphK-133 1 which is the main enzyme responsible for the production of S1P in 134 them[22] , [24] . Phosphorylation of host SphK-1 acts as a key regulating factor 135 for its activity. SphK-1 selectively binds to phosphatidylserine in the membrane 136 and phosphorylation at serine 225 is essential for its increased selective 137 membrane binding capability [28] . Intracellular erythrocytic S1P binds to 138 deoxygenated-hemoglobin, translocates to the membrane and mediates the 139 release of the glycolytic enzyme, GAPDH, which in turn regulates the 140 erythrocytic glycolysis pathway [17] . Apart from being synthesized within the 141 erythrocytes, S1P gets secreted out in the blood plasma via a specific S1P 142 transporter major facilitator superfamily transporter (Mfsd2b) [31] . 143 With this background, we aimed to study the role of host SphK-1 in regulation 144 of parasite growth inside the host erythrocytes. We demonstrated inhibition of The data for all the assays are expressed as the mean ± standard deviation (SD) 305 of three independent experiments done in triplicates. SphK-1 levels was found after treatment with DMS in parasite infected 317 erythrocytes as compared to control by two different technique. (Fig. 1a) . (Fig. 1b) . Moreover, the phosphorylated form of host SphK-1 326 (pSphK-1) was significantly reduced in parasite infected erythrocytes and 327 uninfected erythrocyte following DMS treatment. The band intensities were 328 quantified to confirm the relative changes in both level of SphK-1 and 329 phosphorylation status (Fig. 1b) . 330 Similar results were obtained in a study done parallelly wherein, host SphK-1 331 level and activity was found to be regulated upon parasite infection to human (Supplementary Figure 1, 2 (A-H) ). Interestingly, the S1P level in DMS- After treatment incubation was done for 15min at 37 and we found that in 364 treated sample NBD-sphingosine get less incorporated in parasite as well as on 365 erythrocyte membrane as compared to the control one. (Fig. 1d) . 366 This data suggests that inhibition of Sphk-1 by DMS causes less uptake of 367 NBP-sphingosine as well as less production of S1P which is supported via LC- revealed a moderate to potent anti-malarial activity of DMS with a significant 377 reduction in the parasite load, with IC 50 value attended at 14 µM (Fig. 2a) . To 378 examine its impact on stage specific inhibition of parasite progression, highly 379 synchronized ring stage parasites were treated with 10 µM DMS and their 380 development were monitored at different time intervals (0, 18, 34, 45 hpi) by 381 preparing thin blood smears of the treated and untreated infected erythrocytes. 382 As observed in the blood smears, DMS drastically affected progression of the 383 parasite from rings to trophozoites, stalling the parasite progress at the ring 384 stage as compared to the untreated parasite infected control. Halt in the parasite 385 growth could be accounted to the formation of 'pyknotic body' after 36 hours of 386 the treatment (Fig. 2b) . This progression arrest coincided with a significant drop 387 in the S1P levels of the erythrocytes after DMS treatment. These findings 388 strongly support the hypothesis, which suggested that SphK-1 mediated 389 production of S1P plays an important role in Plasmodium growth and (Fig. 2c) . Similar observation could also be inferred 397 from the experiments involving uninfected erythrocytes treated with DMS ( Fig.   398 2c). The intra-erythrocytic stages of P. falciparum lack a functional citric acid cycle 401 and is largely reliant on glycolysis to fulfill its very substantial energy 402 requirements[36] , [37] . Erythrocytes infected with mature trophozoite stage 403 parasites consume glucose up to two folds of magnitude faster than uninfected 404 erythrocytes, eventually converting it to lactic acid[10] , [11] , [38] . To dissect this 405 mechanism of SphK-1 dependent growth progression in parasite infected 406 erythrocytes, and its link to glycolysis, we estimated the amount of lactate 407 formation, an indicator of glycolytic process, in both infected and uninfected 408 erythrocytes in presence of 10 µM DMS for 3 hours. The findings suggested a 409 prominent reduction in lactate production in DMS-treated infected and 410 uninfected erythrocytes, as compared to respective untreated controls (Fig. 3a) . 411 Interestingly, parasite stage-specific estimation of lactate levels during intra 412 erythrocytic cycle, represented predominant decrease in lactate production, as 413 clearly evident in rings, trophozoites and schizonts (Fig. 3b) , following 414 treatment with 10 µM of DMS for 3 hour. These data depict that; lowering of 415 S1P levels by DMS-based inhibition of host SphK1 can lead to compromised 416 glycolysis, which is manifested as reduced lactate levels in intra-erythrocytic 417 cycle of P. falciparum. 418 To gain further insight, whether the observed metabolic alterations after 419 inhibitor treatment were mediated specifically through erythrocytes or it directly 420 impacted the parasite, we have elucidated the changes in lactate levels in host-421 free parasite isolated by saponin lysis, in response to the inhibitor. To 422 determine the intrinsic lactate level of the trophozoite stage along with the 423 saponin lysed host-free parasites were treated with the inhibitor for 2 hours. 424 Interestingly, the lactate levels were found to be lowered as compared to their 425 respective untreated controls except in the case of saponin lysed parasites 426 wherein, there was no significant difference in the lactate levels of DMS treated 427 and untreated parasites could be detected (Fig. 3c) . Lowering of lactate levels 428 could be accountable to either down regulated glycolysis rate and/or reduced 429 glucose uptake in trophozoite infected and uninfected erythrocytes. However, 430 saponin lysed/host-free DMS treated trophozoites demonstrated negligible 431 difference in the lactate levels as compared to the untreated control, suggesting 432 erythrocytes as the mediator of S1P-dependent glycolysis not the parasite (Fig.   433 3c). Altogether, these readouts suggested that host SphK-1 contributes to the 434 regulation of glycolysis and its effect on parasite growth is mediated solely 435 through the erythrocyte.
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Inhibition of host SphK-1 activity by specific inhibitor DMS decreases both
399
Inhibition of erythrocyte SphK-1 results in decrease in lactate production
436
Abrogated S1P synthesis results in reduced glucose uptake 437 Further, we investigated the role of S1P in glucose uptake and glycolysis, as (Fig. 4a) . The fluorescence intensities were plotted using Image J for the 453 treated and untreated cells indicating the same (Fig. 4a) . To confirm whether 454 18 the impaired uptake of glucose analogue in DMS-treated infected erythrocytes 455 was due to dysregulated glycolysis but not compromised cell viability, we used 456 a strategy using dual dye-based assay. Regarding this, we have used Syto9 in 457 combination with Propidium Iodide (Thermo Fisher Scientific, Waltham, 458 Massachusetts, US) to delineate viability in DMS-treated infected erythrocytes. 459 The finding revealed that the viability was uncompromised in DMS-treated 460 infected erythrocytes with significant reduction in 2-NBDG uptake, suggesting 461 the impairment in glucose uptake was mainly due to altered S1P level following 462 host SphK-1 inhibition by DMS. Further, flow cytometry analysis of 2-NBDG 463 uptake in DMS-treated infected erythrocytes demonstrated a 10-fold shift in 464 fluorescence intensity indicating enhanced uptake of 2-NBDG, whereas, the 465 untreated infected erythrocytes showed severe depletion in 2-NBDG uptake, as 466 shown by diminished intensity peak in representative histogram (Fig. 4b) . 467 These results suggested that the uptake of glucose analogue, a signature of 468 healthy glycolysis, was strongly repressed by the host SphK-1 inhibition as 469 compared to their respective controls. separated for probing with anti-GAPDH mouse antibody. As expected, DMS 482 treatment restricted the translocation of GAPDH to the erythrocyte membrane, 483 as evident in immunoblot and its respective band intensities in both membrane 484 and cytosolic fractions (Fig. 5a) . These findings confirmed low release of 485 GAPDH to the cytosol due to altered glycolysis in DMS-treated infected 486 erythrocytes. Further, we visualized the localization of GAPDH in the cells by 487 immunolabelling using confocal imaging. After DMS treatment, GAPDH was 488 mainly restricted to the erythrocytic membrane rather than translocating to the 489 cytosol, suggesting decreased glycolysis, which can be corroborated to our 490 previous findings (Fig. 5b) . Collectively, these results suggested low S1P levels 491 in DMS-treated infected erythrocytes can lead to aborted glycolysis. To achieve this, we targeted host SphK-1 activity by using a specific inhibitor 520 DMS, which completely depleted the S1P levels in both IC and EC of infected 521 erythrocytes, leading to stalled the parasitic growth and progression with 522 formation of 'pyknotic bodies' (Fig. 1, 2) . To negate the possibility of DMS-523 enforced topological alterations in infected erythrocytes as the basis of aborted 524 parasite growth and invasion, we have performed SEM-based analysis of both 525 uninfected and infected erythrocyte membranes after DMS treatment. To 526 emphasize, there was no significant changes could be identified in membrane 527 structures of infected erythrocytes even after DMS treatment (Fig. 2c) . Similar 528 inference was drawn from the experiment involving uninfected erythrocytes 529 with DMS ( Fig. 2c) . Since erythrocytes mainly harbor SphK-1, but no S1P 530 receptor for its innate signaling, we hypothesized that inhibiting host-SphK1, 531 might be attenuating the host-S1P dependent parasite survival mechanism as (Fig. 2, 3) . This data strongly advocated the role of 543 host-SphK1 in regulation of glycolysis-dependent growth and progression of 544 parasites. Further, to confirm the hypothesis, which suggested that altered 545 glycolysis of intra-erythrocytic cycles is mediated specifically through 546 erythrocytes not via the parasites; we also estimated the lactate levels in DMS-547 treated saponized/host-free parasites, as a proof-of-concept. The observation 548 clearly ruled out the involvement of parasite-mediated glycolysis, as no change 549 in lactate levels could be detected in host-free parasites (Fig. 3) . To elucidate 550 the impact of host SphK-1 inhibition on glucose uptake, during intra-551 erythrocytic development, we have measured the live uptake of glucose using a 552 fluorescent-labeled glucose analogue (2-NBDG). The results presented 553 abrogated glucose uptake in DMS-treated infected erythrocytes, imposing a 554 direct role of host-SphK-1 in regulation of glycolysis ( Fig. 4) . 555 According to a recent study by K Sun et al., SphK-1 activity gets elevated in 556 erythrocytes under hypoxic conditions, leading to enhanced S1P level and 557 thereby, increasing its binding to deoxygenated hemoglobin (deoxy-Hb). (Fig. 5) . To summarize, our study highlights two 567 important findings; firstly, the inhibition of host SphK-1 activity can abrogate 568 intra-erythrocytic growth and progression of P. falciparum, and secondly, 569 diminished S1P levels can lead to host-mediated altered glycolysis resulting in 570 growth retardation of parasites (Fig. 6) . Overall, this study introduces SphK-571 1/S1P signaling nexus in erythrocytes as the alternate pathway for P. falciparum 
